Novartis AG (Novartis) discovers, develops, manufactures, and commercializes pharmaceutical products, and generic and biosimilar medicines. It offers products to treat cancer, cardiovascular, dermatological, neurological, ophthalmic, respiratory, and infectious diseases, hematology and immune disorders. The company operates its business through single segments: Innovative Medicines.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Through its R&D efforts, the company strives to discover and develop new drugs and new formulations of existing products. Major pipeline products include Scemblix for chronic myeloid leukemia; AVXS-101 for spinal muscular atrophy; Beovu for Diabetic retinopathy; Cosentyx for Giant cell arteritis (GCA); LOU064 for relapsing multiple sclerosis; and JDQ443 for Non-small cell lung cancer among others. In FY2023, the company spent US$8,600 million on R&D, which is 22.6% of total revenue. It has major R&D facilities in Basel, Switzerland; Cambridge (Massachusetts); San Diego, California; Emeryville, California; and East Hanover (New Jersey). Novartis has collaborative arrangements with other pharmaceutical and biotechnology companies to develop and commercialize product candidates. The BioMedical Research division conducts drug discovery research and early clinical development trials for its Innovative Medicines segment. The company owns numerous US and foreign patents covering processes for manufacturing a product and particular uses of that product.